Recombinant CD23 (Lumiliximab Biosimilar) 抗体
This Human Chimeric antibody specifically detects CD23 (Lumiliximab Biosimilar) in FACS 和 IP. It exhibits reactivity toward 人.
产品编号 ABIN7543172
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant CD23 (Lumiliximab Biosimilar) 抗体 (ABIN7543172)
抗原
CD23 (Lumiliximab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Human
克隆类型
Chimeric
标记
非结合性
应用范围
Flow Cytometry (FACS), Immunoprecipitation (IP)
克隆位点
IDEC-152
-
-
原理
- Anti-CD23 [IDEC-152 (Lumiliximab, 6G5) ], Human IgG1, kappa
-
特异性
- This antibody is specific for human CD23.
-
产品特性
-
Original Species of Ab: Rhesus Macaque
Original Format of Ab: IgG1
-
纯化方法
- Protein A affinity purified
-
免疫原
- The original chimeric antibody was generated from a monkey immunized with human CD23. Later on the chimeric version of the antibody was generated by cloning the variable regions of the antibody into human constant regions.
-
亚型
- IgG1 kappa
-
-
-
-
应用备注
- This antibody is also known as Gomiliximab. It binds CD23 or FCER2, a membrane protein and a "low affinity" receptor for IgE. It is also involved in IgE regulation and inflammation in allergic disorders, such as allergic rhinitis and allergic asthma. Phase I clinical trials in patients with allergic asthma revealed that IDEC-152 is safe and well-tolerated (PMID: 13679816). This antibody is also reported to have antitumor activity against chronic lymphocytic leukemia (CLL) in clinical trials (Woodworth et al., 2004, Byrd et al., 2004). Phase 1 study of Lumiliximab in patients with relapsed or refractory chronic lymphocytic leukemia reported that it was well tolerated and had clinical activity in patients. Flow cytometric analyses of blood samples were conducted to assess changes in lymphocyte subsets and to study both CD23 expression and binding of lumiliximab during the treatment (PMID: 17671129). This antibody also causes apoptosis in vitro and in vivo in CLL cells and drug-resistant lymphoma cells (Pathan et al., 2004, Zou et al., 2004). Lumiliximab was also found to inhibit allergen-induced responses in antigen-presenting cells and may be involved in modulating antigen-presenting cells and reducing T H 2-type immune responses (PMID: 16210051). This antibody was also used in the detection of human CD23 in the B cell-derived exosomes using immunoprecipitation (PMID: 20876574).
-
说明
-
This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques.
-
限制
- 仅限研究用
-
-
-
浓度
- 1 mg/mL
-
缓冲液
- PBS with 0.02 % Proclin 300.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
- CD23 (Lumiliximab Biosimilar)
-
物质类
- Biosimilar
-
背景
- Gomiliximab, FCER2, BLAST-2, FcεRII, Fc-epsilon-RII, Low affinity immunoglobulin epsilon Fc receptor, C-type lectin domain family 4 member J, Immunoglobulin E-binding factor, Lymphocyte IgE receptor
-
UniProt
- P06734
抗原
-
You are here:
